• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nucleic Acid Therapeutics >Antisense Oligonucleotides As Potential Therapeutics for Type 2 Diabetes
【24h】

Antisense Oligonucleotides As Potential Therapeutics for Type 2 Diabetes

机译：反义寡核苷酸作为2型糖尿病的潜在治疗剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from inefficient signaling and insufficient production of insulin. Conventional management of T2D has largely relied on small molecule-based oral hypoglycemic medicines, which do not halt the progression of the disease due to limited efficacy and induce adverse effects as well. To this end, antisense oligonucleotide has attracted immense attention in developing antidiabetic agents because of their ability to downregulate the expression of disease-causing genes at the RNA and protein level. To date, seven antisense agents have been approved by the United States Food and Drug Administration for therapies of a variety of human maladies, including genetic disorders. Herein, we provide a comprehensive review of antisense molecules developed for suppressing the causative genes believed to be responsible for insulin resistance and hyperglycemia toward preventing and treating T2D.
机译：2型糖尿病（T2D）是一种慢性代谢性疾病，其特征是由于信号传导效率低下和胰岛素分泌不足而导致持续性高血糖。T2D的常规治疗在很大程度上依赖于小分子口服降糖药物，由于疗效有限，这些药物不会阻止疾病的进展，也会引起不良反应。在这方面，反义寡核苷酸由于能够在RNA和蛋白质水平下调致病基因的表达，在开发抗糖尿病药物方面引起了极大的关注。迄今为止，美国食品和药物管理局已批准七种反义药物用于治疗包括遗传疾病在内的多种人类疾病。在此，我们对用于抑制被认为与胰岛素抵抗和高血糖有关的致病基因以预防和治疗T2D的反义分子进行了全面综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号